Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy

Inclusion Criteria: * Patients infected with HIV-1 type B or CRF02. * ≥ 18 years old * Patients who have been receiving antiretroviral therapy for at least 5 years, and whose treatment has been stable for at least 6 months. * Patients whose plasma viral load has been undetectable (below 200 copies/mL) over the last 24 months, and \< 50 copies/mL for at least 12 months. * Patients with an R5\* tropic virus, as determined through DNA and with CD4 nadir ≥ 100/mm3 * Patients presenting with clinical lipohypertrophy recognized by themselves and by their doctors, and defined by increased volume of the abdominal and/or thoracic and/or cervical area (buffalo hump). * Patients who have never been treated with raltegravir. * Patients who have never been treated with maraviroc. * Efficient contraception for women * Free and informed written consent, signed by the patient and the investigator. * Patients with health insurance. \* To increase the certainty of selecting patients with an R5 virus, the HIV-1 tropism will be determined by the genotype method and interpreted with the Geno2pheno\[coreceptor\] algorithm and a false positive rate threshold for X4 virus at 20%, rather than the usual 10%. Exclusion Criteria: * X4, X4/5 or undetermined tropism of the HIV virus. * HIV-2 or coinfection HIV-1/HIV-2. * Chronic viral hepatitis B. * Chronic viral hepatitis C requiring specific treatment over the first 24 weeks. * Treatment with growth hormones. * Hypolipemic or diabetes treatment, begu…